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Abstract Artemisinin, a constituent of Artemisia annua L., is a well-known antimalarial drug. Artemisinin-type drugs
also inhibit cancer growth in vitro and in vivo. Herbal extracts of A. annua inhibit the growth of cancer cell lines. Here, we
report on the use of capsules containing powder of Herba Artemisiae annuae to treat pet sarcoma. The surgical tumor
removal as standard treatment was supplemented by adjuvant therapy with A. annua. One cat and one dog with fibro-
sarcoma survived 40 and 37 months, respectively, without tumor relapse. Two other dogs suffering from fibrosarcoma and
hemangioendothelial sarcoma also showed complete remission and are still alive after 39 and 26 months, respectively. A.
annua was well tolerated without noticeable side effects. These four cases indicate that A. annua may be a promising herbal
drug for cancer therapy.
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1 Introduction
Artemisia annua L. is a medicinal plant used in traditional
Chinese medicine to treat fever and chills. In the late 1960
and 1970 s, Chinese scientists discovered that artemisinin,
one of the constituents of A. annua, is active against
malaria [1, 2]. The anti-malarial activity of artemisinin was
confirmed by many scientists worldwide. Nowadays,
derivatives of artemisinin such as artemether and artesu-
nate are well-established drugs in the fight against malaria.
In the 1990 s, the pioneering work by us and others showed
that artemisinin and its derivatives inhibit cancer growth
in vitro [3–7]. In subsequent years, it turned out that arte-
misinin-type compounds are able to kill cell lines of many
different tumor types, e.g. leukemia, lymphoma, mela-
noma, brain tumors, carcinoma of the colon, breast, ovary,
lung, kidney, and many others [8–10]. Investigations into
the mode of action revealed that artemisinin may form
active radical oxygen species and carbon-centered radical
molecules leading to oxidative stress [11–15], DNA dam-
age [16, 17], adduct formation of specific target proteins
[18, 19], cell cycle arrest [20], interaction with signal
transduction pathways [21–26], induction of apoptosis and
autophagy [7, 27–31], and inhibition of angiogenesis [32–
35]. Artemisinin-type drugs have also been shown to act
against cancer in vivo using transplantable murine synge-
neic tumors [6, 36–38] and human xenograft tumors [32,
39–47]. The clinical efficacy has been described in several
reports on the use of these compounds [48, 49] and more
recently in clinical trials in veterinary tumors (spontaneous
tumors in dogs) and human cervical carcinoma [50, 51].
Whereas artemisinin and its derivatives are well ana-
lyzed both in malaria and cancer, less is known about the
bioactivity of plant extracts of A. annua. The antimalarial
activity of A. annua tea or extracts has been investigated in
animal experiments [52, 53]. Malaria treatment with A.
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annua tea is being widely used in Africa by the indigenous
population outside official health care systems [54–60].
Whether or not Herba Artemisiae annuae is active against
cancer in vivo is unknown, although cytotoxic activity
in vitro has been reported [61, 62].
Here, we report on the use of Herba A. annuae in pets
suffering from sarcoma. Dogs and cats may spontaneously
develop cancer, making them to suitable subjects for
pharmacological intervention [63]. Treatment of tumors in
three dogs and one cat showed a considerable response of
tumors to the herbal preparation.
2 Materials and Methods
2.1 Material
Artemisia annua L. preparations (Luparte) were obtained
from Lupovet GmbH (Mu¨llheim/Baden, Germany). Using
a semiautomated device 450 or 150 mg of the 1:30
extracted and pulverized Herba A. annuae were for tech-
nical reasons enriched with 50 or 17 mg Inulin and
enclosed in capsules size ‘‘O’’ or ‘‘4’’, respectively.
2.2 Thin Layer Chromatography (TLC)
The method was performed as described with modifications
[64]. The test solution was prepared by dissolving 3 g
Herba A. annuae powder in 50 mL petroleum ether pre-
heated to 60–90 C, refluxing for 1 h and filtering. The
filtrate was evaporated to dryness and the resulting residue
was dissolved in 30 mL hexane. The solution was parti-
tioned with 20 % acetonitrile–water twice or trice and the
combined acetonitrile phases were evaporated to dryness.
The evaporated dry residue was dissolved in 0.5 mL
ethanol. Artemisinin and scopoletin (each 1 mg/mL) were
used as reference substances (Sigma-Aldrich, Taufkirchen,
Germany).
The thin layer chromatography was performed using Silica
gel 60 F254 plates (Merck, Darmstadt, Germany), onto which
5 lL each of test solution and reference substances were
spotted to the Silica gel plates. The plates were developed in a
chromatographic jar containing mobile phase composed of
cyclohexane/ethylacetate/glacial acetic acid in ratios of
20:10:1. After developing the plate was air dried examined on
day light, UV-light (365 nm) and sprayed with spray reagent
composed of 5 mL anisaldehyde, 10 mL glacial acetic acid
mixed with 85 mL methanol and concentrated H2SO4
2.3 Patients
One female and two male dogs as well as one male cat
between 10 and 13 years were diagnosed with hema-
ngioendothelial sarcoma or fibrosarcoma at the Veterinary
Clinic, Mu¨llheim. All four animals suffered from a grade 3
or 4 tumor at diagnosis (Table 1).
After the decision was made to use Luparte, the serum
iron (normal range between 140 and 170 lg/dL) was mea-
sured. Between blood taking and getting back the serum iron
results from the clinical diagnosis laboratory, iron was given
p.o. b.i.d or intramuscularly every 3 days to mark the iron
affine malignant cells. The initial ‘‘blind’’ dose of orally
given iron (e.g. Ferrosanol capsules 100 mg) was about
100 mg/30 kg b.i.d. or about 100 mg/10 kg weight Urso-
ferran i.m. two times a week. The iron application was
continued for the entire treatment time, and was attuned to
maintain the iron level at 250 ± 30 lg/dL.
From the fourth day onward, the animals were treated p.o.
two to three times daily with one capsule (150 mg in the cat,
450 mg in the dogs) of Herba A. annuae simultaneously.
Table 1 Clinical data of animals
Case 1 Case 2 Case 3 Case 4
Species cat dog dog dog
Breed European Bernese mountain dog Gordon Setter Bernese mountain dog
Gender male male female male
Date of diagnosis Sept 14, 2011 Dec 28, 2011 Oct 18, 2010 Nov, 25, 2011
Age at diagnosis 10 years 10 years 10 years 10 years
Initial Serum Iron (lg/dL) 222 107 85 124
Histology fibrosarcoma fibrosarcoma hemangioendothelial sarcoma fibrosarcoma
Staging, Grading: T3N0M0 T3NxM0 T4N0M0 T3NxM0
Response complete remission complete remission complete remission complete remission
Survival time (months) 40a 37a 39a 26a
Status dead dead alive alive
a at Febr 10, 2014
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3 Results
3.1 Thin Layer Chromatography
As a starting point, we analyzed the composition of the A.
annua powder used for the preparation of the Luparte
capsules by TLC. As shown in Fig. 1, artemisinin was a
minor constituent with an Rf value resembling the authentic
sample Rf and scopoletin was the abundant compound in
the A. annua powder. Capsules filled with this plant pow-
der were used for the therapy of animals suffering from
sarcoma in an adjuvant setting together with initial surgery.
3.2 Case 1
A 10-year old cat was presented on September 14th, 2011
with a highly malignant fibrosarcoma subcutaneously
localized at the lower front flank, which infiltrated muscles
and fat tissue and invaded veins (Fig. 2a; Table 1). The
tumor did not tend to grow in a capsule-like morphology
and revealed marginal fiber formation. Concomitant
inflammation with lymphoplasmacellular dominance and
lymphofollicular proliferation were detectable. The tumor
was removed by surgery and adjuvantly treated with A.
annua (3 capsules 150 mg/day) without iron application
due to high serum iron values. No side effects were
observed. Euthanasia was performed 40 months later on
January 7th, 2014 because of chronic hepatosis. The tumor
was not detectable clinically or by sonography at that time.
3.3 Case 2
A buccally localized, highly malignant mesenchymal neo-
plasia mainly of fibrosarcomatous architecture was diag-
nosed in a 10-year old dog (Bernese mountain dog mix) on
December 28th, 2010 (Fig. 2b; Table 1). The highly prolif-
erating tumor showed tuberous infiltration. Areas of fibro-
blast proliferation were interspersed with capillary shoots. A
massive plasmacellular neutrophilic inflammation with a
high portion of mast cells was superimposed on the tumor.
The tumor was incompletely removed via surgery and trea-
ted with A. annua (2 capsules 450 mg/day) in an adjuvant
manner from the fourth day on after marking the malignant
cells with iron from the Ferrosanol 100 mg capsules. No side
effects were observed. The dog was euthanized 37 months
later on March 20th, 2012 because of uremia. At this time no
tumor relapse was detected.
3.4 Case 3
A 10-year old Gordon Setter with a clinically obvious breast
cancer with a length of about 40 cm and a width of about
10 cm was presented with highly acute course and massive
concomitant edematous inflammation October 18th, 2010.
The tumor was diagnosed as hemangioendothelial sarcoma
with multiple foci (Fig. 2c; Table 1). Capsule formation
took place partially. The tumor foci revealed infiltrating
fibrotic nodes. Two sections of lymph nodes with hemosid-
erosis did not feature metastases. The tumor was operated on
and treated with A. annua (Luparte) (3 capsules a` 450 mg/
day) in an adjuvant manner from the fourth day after iron
identification marked the remaining malignant cells. The
Artemisia capsules were well tolerated without side effects.
Thirty-nine months later, by a phone call in the middle of
January 2014, we learned that the dog is doing well.
3.5 Case 4
A rapidly growing, irregularly confined tarsal tumor was
diagnosed in a 10-year old Bernese mountain dog on
November 25th, 2011. Pathological examination revealed
that the tumor was a highly malignant fibrosarcoma infil-
trating in and fat tissue and invading veins (Fig. 2d; Table 1).
The tumor did not form a capsule and revealed marginal fiber
formation. Concomitant inflammation with lymphoplasma
cellular dominance and lymphofollicular proliferation was
detectable. The fibrosarcoma was surgically removed, a skin
mesh was transplanted on the remaining defect and the dog
Fig. 1 Thin layer chromatography of Herba Artemisiae Annuae
(Luparte). Scopoletin and Artemisinin were used as reference
compounds
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was treated two times daily with capsules containing 450 mg
each for about 2 years. No side effects appeared. Twenty-six
months later, the dog is still healthy without any signs of
relapse.
4 Discussion
In the present investigation, we addressed the question of
whether or not an A. annua preparation is able to inhibit
tumors in vivo. This project was inspired by data we and
others collected, which indicated that A. annua extracts in
addition to isolated artemisinin, may inhibit cancer cells
in vitro[5, 61, 65]. Nevertheless, the question of whether or
not the cytotoxic activity observed in vitro can be trans-
lated to living organisms remains. In many cases this is
unusual. The observations we made with a 1:30 A. annua
extract for the treatment of spontaneous tumors and dogs
and cats are encouraging for starting larger placebo-con-
trolled and randomized clinical trials. Fibrosarcoma and
hemangioendothelial sarcoma are tumor types, which are
primarily treated by surgical removal. Survival times for
dogs with fibrosarcoma treated with surgery range from 7
to 12.2 months. Adding adjuvant radiotherapy improved
outcomes by an average of 743 days [68]. Radiotherapy of
sarcoma in dogs resulted in survival times between 8 and
19.7 months [69–74], whereas the success of chemother-
apy is limited [75]. This is a non-satisfying situation and
novel treatment strategies are urgently required. Here, we
report on four pets suffering from fibrosarcoma or
hemangiosarcoma treated by surgery plus A. annua cap-
sules after the remaining malignant cells were marked with
iron. The combined use of surgery and adjuvant treatment
with iron and A. annua resulted in survival times between
26 and 40 months, and two of the four animals are still
alive. This indicates that adjuvant iron-triggered A. annua
impacts the overall survival rates of dogs suffering from
sarcoma and improves the treatment success over that of
surgery alone. Controlled clinical trials are warranted to
verify these first experiences with iron-triggered A. annua
in pet cancer therapy. The comparative relevance of this
phytochemical trial to human oncology remains to be seen.
As of now, no comparable alternative is known to the
authors.
While there are great efforts to test drugs in vivo in
mice, the value of veterinary tumors as a comparative
in vivo test is frequently underestimated. Most commonly,
murine syngeneic or human xenograft tumors transplanted
into mice are used to test the activity of cytotoxic com-
pounds in vivo. Both model systems have advantages and
disadvantages [66]. Syngeneic and xenograft tumors are
easy to maintain and well-established tumor lines are
available. They are usually maintained intraperitoneally or
subcutaneously, but these are sites that may not be relevant
for the clinical situation. In addition, human xenografts are
transplanted into athymic nude mice, which lack an intact
immune system. More relevant tumor models such as
orthotopic tumors require surgical manipulation and are,
thus, time-and cost-consuming. In addition, the animals
require more care. Therefore, experimentally induced or
Fig. 2 Histology of pet
sarcoma. a Highly malign
fibrosarcoma of the cat case 1
(9 400) b Fibrosarcoma of the
Bernese mountain dog Case 2
(9 600) c Hemangiosarcoma of
the Bernese mountain dog Case
3 (9 400) d Fibrosarcoma of
the Bernese mountain dog Case
4 (9 600)
116 E. Breuer, T. Efferth
123
spontaneously arising veterinary tumors may represent a
promising option [63, 66, 67]. Our own experience with A.
annua and recently published data with artesunate in dog
tumors [51] favorable suggest that veterinary tumors are a
suitable model to test the anticancer activity of drugs
in vivo, before applying them to human cancer patients. In
this way, such trials provide ‘‘comparative oncology’’.
An interesting result was that artemisinin represented
only a minor constituent in A. annua and that scopoletin
was the most abundant phytochemical. It is well known
that A. annua contains a large panel of different secondary
metabolites, including scopoletin, which are cytotoxic [5,
57, 76–79]. The activity of the A. annua preparation in pet
tumors and the presence of large amounts of scopoletin
raise the question of whether scopoletin might contribute to
the anticancer effect of this plant rather than artemisinin.
The in vitro cytotoxicity of scopoletin towards cancer cells
has been previously described [80–82].
In conclusion, the results of the present investigation
give hope that approaches with A. annua may be promising
for the treatment of veterinary tumors. Furthermore, the
analysis of scopoletin and other hydroxylated and meth-
oxylated flavonoids as a therapeutic principle in A. annua
deserves further attention.
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